meaning severity may be difficult to assess. Air bronchograms are often present. When she was reviewed in clinic with worsening breathlessness, there was no evidence that her COP was worsening radiologically, and her breathlessness had not improved with prednisolone. CTPA had excluded chronic thromboembolic pulmonary hypertension; however, studies have shown that CTD patients with antiphospholipid antibodies are more likely to develop PAH, even in absence of thrombosis. Our patient was positive for cardiolipin IgG and IgM. Nonetheless, clinical suspicion was sufficient for the patient to have echocardiography which indicated new onset PAH. Her PAH was severe and symptomatic resulting in urgent admission to a specialist unit. This case highlights the key symptoms and signs which may make clinicians suspect PAH including reduced exercise tolerance and features of right heart failure. Key learning points: Pulmonary involvement in PSS is common and 10-20% of patients develop significant respiratory disease. COP, although a rare ILD in the context of PSS (more common in rheumatoid arthritis), should be suspected in Sjö gren's patients with radiological consolidation who donot respond to antibiotic treatment. The most common subtype of ILD in Sjö gren's is non-specific interstitial pneumonia (fibrosing variant). Along with COP, other less common manifestations include usual interstitial pneumonia and lymphocytic interstitial pneumonitis. These rarer manifestations of ILD are not as clearly identifiableradiologically and may require lungbiopsies. Studies suggest that the main risk factors for lung involvement include smoking, late onset and long evolution of disease. As in this case, pulmonary involvement is commonly associated with hypergammaglobulinaemia and anti-SSA, anti-SSB, ANA and rheumatoid factor positivity. We are not aware of many clinical or serological parameters which could be used to risk stratify whichPSS patients arelikely to develop ILD. PAHshouldbesuspected inpatientswithunderlyingCTDeven inthecontext of pre-existing lung disease such as ILD or COP. Studies suggest that up to 20% of primary Sjö gren's patients may have asymptomatic PAH, therefore PAH should be considered in patients who respond poorly to steroid treatment for suspected ILD. PAH is challenging, as by the time it progresses to symptoms it can be severe and even life threatening. Early diagnosis and appropriate referral to a specialist unit may be critical. Guidance regarding echocardiogram as a tool for detecting PAH in PSS patients would be helpful. Our case illustrates the value of full clinical examination inCTD patients as a raised JVP led to early detection of PAH.
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MANAGEMENT OF GCA AND RA IN PATIENTS WITH CHRONIC SUPPURATIVE LUNG DISEASE
Wah Phin Lee 1 , Anushka Ediriweera 1 , David Derry 1 , and Ognjenka Savanovic-Abel 1 1 Respiratory Medicine, University Hospital Plymouth NHS Trust, Plymouth, United Kingdom Introduction: The diagnosis and management guidelines for giant cell arteritis (GCA) are relatively straightforward. However the diagnosis can be challenging when it is hidden under other inflammatory conditions and management is difficult when affected patient has other co-morbidities especially in the background of chronic suppurative infection. This article demonstrates the challenges in diagnosing and managing such case. Case description: Our patient is an 83-year-old lady who was referred to rheumatology. She has complex medical history of chronic suppurative lung disease with pseudomonas infection. In addition she had previous ESBL urinary tract infection (UTI), deep vein thrombosis and pulmonary embolism. Management of infection is severely limited by her multiple antibiotic intolerances (gentamycin, tobramycin, colomycin, fluoroquinolones, doxycycline, cefaclor, amoxicillin, co-amoxiclav, meropenem, tazobactam/piperallin and ceftazidime). She is on prophylactic cefradine for UTI and prophylacticamoxicillin forlung infection. On presentation, she had inflammatory polyarthritis which was subsequently diagnosed as seronegative rheumatoid arthritis (RA). She had limited therapeutic options owing to chronic suppurative lung disease. She was advised against methotrexate and leflunomide by chest physician. She could not tolerate sulfasalazine twice during the course of her illness due to gastrointestinal side effects and had to stop hydroxychloroquine because of headache and nausea. Therefore, she had to be managed with tapering doses of prednisolone and intraarticular knee injection during flairs.
Nearly two years after her first presentation, she developed recurrent headache. However, there were no other symptoms of giant cell arteritis. On clinical examination her temporal arteries were prominent, thickened and tender to touch but pulsatile. CRP was 88. Ultrasound of temporal arteries showed evidence of inflammation. Biopsy of temporal artery was not performed. She was treated with prednisolone 20 mg daily. She continued treatment for six weeks and showed clinical improvement with normalization of CRP. Her prednisolone dose continued to be tapered successfully. However, she developed complications from treatment, in form of worsening cataract and recurrent urinary tract infections. At the time of article submission, her GCA and RA remain in remission while her prednisolone had been tapered to 9 mg daily. Discussion: Based on NICE guidelines, the treatment of GCA is 60mg of prednisolone for patients with visual symptoms and 40mg of prednisolone for patients without visual symptoms. The risk of infections in highdose glucocorticoids is well-established. A study using administrative data found that GCA patients, when compared with a matched historical cohort, had increased rates of lower respiratory tract infections, UTI, and other serious infections, which are defined as pneumonias, upper urinary tract infections, and sepsis. The rate of infection is the highest in the first six months of treatment during the greatest glucocorticoid exposure. Due to her pre-existing chronic suppurative lung disease, it was deemed to be of too high risk to commence on the standard dose of prednisolone and to adhere to the recommended length of tapering. We have decided to opt for a lower dose (20mg) of prednisolone for 6 weeks and taper after that. The dose was selected based on the risk and benefit assessment of her underlying chronic infection. There may be difficulties in future management because usual steroid-sparring agents (DMARDs and biologics) would becontra-indicated. According to NICE guidelines, the diagnosis of GCA should be confirmed on temporal artery biopsy (TAB). We have decided that the clinical and imaging evidences were sufficient to diagnose her GCA. We felt that temporal artery biopsy would not add or change her therapeutic management. Key learning points: This case highlights the difficulty in managing multiple inflammatory conditions in the presence of complex chronic infections. In case in which all recommended treatments are contraindicated, we have to be prepared to deviate from the recommended guidelines and make decisionbasedon patient tailored risk benefit assessment. This case also serves as a reminder of the importance of shared decisionmaking and multi-disciplinary approach in managing complex clinical case.She isatriskof developingcomplications fromprolonged glucocorticoid use, and therefore we have involved the local respiratory team and discussed the case in the rheumatology multi-disciplinary (MDT) meeting.
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THE PARADOX
Mohammed Saleh 1 , and Charlotte Jenkins 2 1 Rheumatology, Wales Deanery, Cardiff, United Kingdom, and 2 Rheumatology Services, Princess of Wales Hospital, Bridgend, United Kingdom Introduction: Incidental findings on investigations is not uncommon in rheumatology practice. Here such an incidental finding has led to dramatic change in the management of the underlying disease. Case description: A 38-year-old gentleman known to have ankylosing spondylitis (AS) since 2008, with radiologically evident sacroilitis on X-ray and MRI, was reviewed routinely in clinic and reported pain and restriction of neck movement and subsequent MRI cervical spine in April 2017 has shown incidental finding of apical fibrosis, but noAS activity. He denied constitutional and respiratory symptoms apart from occasional dry cough. Chest X-ray and high resolution CT scan confirmed the same findings of apical fibrosis in addition to bilateral reticulonodular and fisural changes. Blood tests showed angiotensin converting Eezyme level ACE 65 U/L(normalrange 8-65), C-reactive protein <5. Bronchoscopy/biopsy showed non-caseating epitheliod granuloma. ZN stain and culture showed no TB infection. He was reviewed by the respiratory team and felt findings could conceivablyfit with sarcoidosis. His dry cough has improved after Benepali was discontinued in June 2017 and no steroids were given. However, had a flare of AS symptoms (ribs and lower back pain and stiffness,right SIJ pain) despite regularetoricoxib and required to start onsecukinumab. Discussion: Benepali (Etanercept biosimilar) sounds not different from the originator biologic in causing sarcoid-like reactions commonly POSTER PRESENTATIONS 27 September 2019 i31
